Navigation Links
Ex- White House Drug Spokesman Urges 'Double Drug Treatment'; Bob Weiner and Policy Analyst Zoe Pagonis Highlight 'Drug War's Wrong Focus'
Date:7/27/2009

will buy and sell drugs."

Weiner and Pagonis conclude, "President Barack Obama is right to increase the National Drug Control budget by $224.3 million, but the focus is not where it's needed most. If they really want to stop crime and prevent addiction, the administration and Congress need to give treatment and prevention programs far more standing in the nation's drug control budget."

LINK TO ARTICLE: www.weinerpublic.com/20090727.doc

Contact: Bob Weiner/Zoe Pagonis 301-283-0821 or 202-329-1700


'/>"/>
SOURCE Robert Weiner Associates
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. NCPA: White House Has Ideas on How to Ration Health Care
2. Integrated Healthcare Association Releases White Paper on Pay for Performance
3. BurrellesLuce White Paper Gives Advice on Turning Twitter Connections Into Community Building Blocks
4. New White Paper from The Beryl Institute Provides Insights to Generations
5. British Medical Journal Report Supports SCHS White Paper on Statins
6. Statement About Agreement With White House and Senate Finance Committee on Health Reform
7. Statement by Jim OHara, Director, Produce Safety Project, in Response to the White House Announcement on the Proposed FDA Rule on Produce Safety
8. Cancer Gap Between Whites, Blacks May Be Biological in Part
9. Betty White Talks Animals With The Grandfather of Possibilities
10. What is different in reflux esophagitis between African-Americans and non-Hispanic whites?
11. USAID Brings White House Service Initiative to Baltimore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 Alliance Healthcare ... and wellness for those in need in San Diego ... local organizations through its Mission Support Grants program with ... non-profit organizations applied for AHF’s Mission Support Grants program. ... AHF’s board of trustees and program committee, as well ...
(Date:3/4/2015)... Houston, Texas (PRWEB) March 04, 2015 ... blog , Endometriosis can be a painful ... endometrium) starts spreading outside of the uterus leading to ... and their families. Endometriosis can have a terrible effect ... symptoms. It is also the most common cause of ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Organic Valley, the ... brand, today announced its cause campaign to Save the Bros, ... and is making a difference to Bros everywhere. To ... Youtube and Facebook. The video was named Adweek’s best ... in Forbes, Mashable and Digiday, among other media outlets. ...
(Date:3/4/2015)... Springfield, VA (PRWEB) March 04, 2015 ... announce that John Dvorak has joined the ... responsible for charting the technology focus for the company, ... , Mr. Dvorak brings 20 years of experience as ... he served in diverse roles at the FBI including ...
(Date:3/4/2015)... 2015 The Alliance for Regenerative ... its upcoming fifth annual Advanced Therapies Summit next ... event this year will feature five expert-led interactive ... the field’s leading companies and organizations. , ... and clinical researchers from the advanced therapies community ...
Breaking Medicine News(10 mins):Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3
... drug Rimonabant (Acomplia) a selective cannabinoid receptor blocker (CB1), ... Supplementation with 20 milligrams of rimonabant a day resulted ... circumference -- a marker of cardiovascularly dangerous visceral fat. ... prevalence of metabolic syndrome in overweight/obese patients. ...
... benefit more from treatment combining cognitive behavioral therapy with ... physicians. ,Panic disorder is one of the most ... patients meeting the criteria for panic disorder were randomly ... combining medication and up to six sessions of cognitive-behavioral ...
... A new study shows people suffering from the bone-thinning ... having celiac disease //, a condition in which people ... for celiac disease can markedly improve bone mineral density, ... celiac disease also tend to have thinning bones, but ...
... gene variant that may increase the risk of late-onset ... improved understanding of the disease and new prevention and ... that specific changes in the gene in a protein ... Alzheimer’s. ,In previous studies, researchers studied Alzheimer’s patients ...
... chemotherapy (IPHC) and is currently //being considered as the ... treatment are connected to a series of tubes and ... the abdominal cavity for a couple of houirs. ... drug while the direct contact helps kill the carcinogenic ...
... Researchers say they may have discovered a potential form ... ,More than 1 million Americans are estimated to ... forms of inflammatory bowel disease. The conditions, can be ... the digestive tracts. Patients with inflammatory bowel disease suffer ...
Cached Medicine News:
(Date:3/4/2015)... , March 4, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... will ring The Opening Bell ® of the ... 2015. Asterias began trading as an NYSE MKT listed ... York Stock Exchange is a trusted partner to Asterias ...
(Date:3/4/2015)... OAKS, Calif. , March 4, 2015 ... Board of Directors today declared a $0.79 per share ... will be paid on June 5, 2015, to all ... on May 14, 2015.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:3/4/2015)... 4, 2015  NxStage Medical, Inc. (Nasdaq: NXTM ... that Jeffrey H. Burbank , Chief Executive Officer, will ... Miami, FL on Wednesday, March 11 th ... the event will be made available at http://ir.nxstage.com ... NxStage NxStage Medical, Inc. (Nasdaq: NXTM ...
Breaking Medicine Technology:Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3Amgen Announces 2015 Second Quarter Dividend 2Amgen Announces 2015 Second Quarter Dividend 3NxStage to Present at the Barclays Capital Global Healthcare Conference 2
... Based on its recent analysis of the personal emergency ... with the 2010 North American Frost & Sullivan Award ... BeClose System and its applications in the "aging independently" ... While PERS have provided a health monitoring service for ...
... Inc. (Nasdaq: OPTR ) today announced that the ... the Company,s New Drug Application (NDA) for fidaxomicin for the ... reducing the risk of recurrence when used for treatment of ... for six-month Priority Review, and has assigned a Prescription Drug ...
Cached Medicine Technology:Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 2Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 3Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 4
Shandon Slide Mailers and Envelopes...
Shandon Stackable Slide Storage Cabinet...
Shandon Slide File Storage System...
Shandon Plastic Slide Boxes...
Medicine Products: